According to the recently released Personalized Medicines Coalition 2017 Progress report, the FDA approved a record number of 16 new personalized medicines in 2017.
According to the recently released Personalized Medicines Coalition (PMC) 2017 Progress report, the FDA approved a record number of 16 new personalized medicines in 2017.
In fact, PMC reported that in the past 4 years, more than 1 in every 4 drug approvals has been of a personalized medicine. In 2017, the agency also approved the first personalized medicine biosimilar in the United States: trastuzumab-dkst, (Ogivri) received FDA approval in December 2017 to treat HER2-positive breast cancer. Trastuzumab-dkst is referenced on trastuzumab (Herceptin), which received FDA approval in 1998.
In addition, the agency approved the first 3 gene therapies for the first time in the United States. Two of the gene therapies, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), are CAR T-cell treatments for acute lymphoblastic leukemia and large B-cell lymphoma, respectively. The final gene therapy, voretigene neparvovec-rzyl (Luxturna) was approved for the treatment of retinol dystrophy.
“We’re increasingly able to identify patient benefit earlier in the development process because of the ability to better target medicines to the underlying mechanisms of disease,” said FDA Commissioner Scott Gottlieb, MD, of these approvals.
The FDA also expanded indications in 2017 for 15 different personalized medicines, including pembrolizumab (Keytruda). Pembrolizumab is now indicated to treat all solid tumor types in advanced cancers with microsatellite instability-high or mismatch-repair deficiency. The PMC report notes that this marks the first time an oncology drug has been approved based on a biomarker, regardless of where the tumor is located within the body.
Notably, for the second time in their histories, the FDA and CMS announced a joint approval and coverage decision under the Parallel Review program in 2017. This approval was granted to a next-generation sequencing (NGS) testing platform, Foundation Medicine’s FoundationOne CDx. Additionally, for the first time, the FDA authorized the commercialization of health-related genetic tests that are sold directly to consumers, such as the 23andMe Personal Genome Service Genetic Health Risk test.
“FDA has an important role to play in advancing this targeted approach to treating disease by building a modern framework that ensures we’re providing the guidance and resources needed to efficiently develop these novel products using new technology,” said Gottlieb.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.